Clinical Trial Update: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic expanded gamma delta T cells combined with GD2-targeted chemoimmunotherapy in relapsed/refractory neuroblastoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• Allogeneic Expanded Gamma Delta T Cells with GD2 Chemoimmunotherapy

Snippet

Sponsor: Emory University | Conditions: Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Status: RECRUITING